Fimepinostat (CUDC-907)

Name: Fimepinostat (CUDC-907)
Brand: Selleck Chemicals
SKU: S2759
Rating: 5 (28 reviews)

For research use only.

Catalog No.S2759

28 publications

Fimepinostat (CUDC-907) Chemical Structure

CAS No. 1339928-25-4

CUDC-907 is a dual PI3K and HDAC inhibitor for PI3Kα and HDAC1/2/3/10 with IC50 of 19 nM and 1.7 nM/5 nM/1.8 nM/2.8 nM, respectively. CUDC-907 induces cell cycle arrest and apoptosis in breast cancer cells. Phase 1.

Selleck's Fimepinostat (CUDC-907) has been cited by 28 publications

Blood Cancer J, 2021, 11(6):111

PubMed: 34099621 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2021, 10.1007/s00280-020-04210-0

PubMed: 33392641 ( click the link to review the publication )

Exp Hematol Oncol, 2021, 10(1):19

PubMed: 33663586 ( click the link to review the publication )

Haematologica, 2020, 12;haematol.2019.233445

PubMed: 32165486 ( click the link to review the publication )

Cell Death Dis, 2020, 11(9):765

PubMed: 32943605 ( click the link to review the publication )

Cancer Sci, 2020, 112(1):133-143

PubMed: 33067904 ( click the link to review the publication )

J Cell Mol Med, 2020, 27

PubMed: 32459381 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2020, 10.1007/s00280-019-04022-x

PubMed: 31901955 ( click the link to review the publication )

J Cell Commun Signal, 2020, 10.1007

PubMed: 32200503 ( click the link to review the publication )

Gastroenterology, 2019, 157(6):1615-1629

PubMed: 31446059 ( click the link to review the publication )

Haematologica, 2019, 104(11):2225-2240

PubMed: 30819918 ( click the link to review the publication )

Oncologist, 2019, 24(8):e740-e748

PubMed: 30696721 ( click the link to review the publication )

Int J Mol Med, 2019, 44(5):1789-1800

PubMed: 31545402 ( click the link to review the publication )

ACS Omega, 2019, 4(22):19895-19904

PubMed: 31788622 ( click the link to review the publication )

Nucleic Acids Res, 2018, 46(10):5029-5049

PubMed: 29596642 ( click the link to review the publication )

Cancer Res, 2018, 78(20):5731-5740

PubMed: 30135193 ( click the link to review the publication )

Sci Signal, 2018, 11(557)

PubMed: 30459282 ( click the link to review the publication )

EBioMedicine, 2018, 28:80-89

PubMed: 29396295 ( click the link to review the publication )

Br J Haematol, 2018, 182(6):921-924

PubMed: 28771685 ( click the link to review the publication )

J Cell Mol Med, 2018, 10.1111/jcmm.13935

PubMed: 30353642 ( click the link to review the publication )

Biochem Pharmacol, 2018, 148:13-26

PubMed: 29208365 ( click the link to review the publication )

Front Cell Infect Microbiol, 2018, 8:191

PubMed: 29942796 ( click the link to review the publication )

Invest New Drugs, 2018, 36(1):10-19

PubMed: 28819699 ( click the link to review the publication )

Stem Cells Dev, 2017, 26(5):353-362

PubMed: 27829312 ( click the link to review the publication )
Int J Parasitol Drugs Drug Resist, 2017, 7(1):51-60

PubMed: 28110187 ( click the link to review the publication )

Saudi J Gastroenterol, 2017, 23(1):34-38

PubMed: 28139498 ( click the link to review the publication )

Mol Pharm, 2016, 13(3):784-94

PubMed: 26796063 ( click the link to review the publication )

Am J Transl Res, 2014, 6(5):471-493

PubMed: 25360213 ( click the link to review the publication )

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description

Targets

HDAC1 ^[1] (Cell-free assay)	HDAC3 ^[1] (Cell-free assay)	HDAC10 ^[1] (Cell-free assay)	HDAC2 ^[1] (Cell-free assay)	HDAC11 ^[1] (Cell-free assay)	View More
1.7 nM	1.8 nM	2.8 nM	5.0 nM	5.4 nM	View More

In vitro

CUDC-907 inhibits other PI3K isoforms such as PI3Kβ, PI3Kγ, PI3Kδ, PI3KɑH1047R and PI3KɑE545K with IC50 of 54 nM, 311 nM, 39 nM, 73 nM and 62 nM, respectively. Moreover, CUDC-907 also prevents HDAC subtypes HDAC8, HDAC6 and HDAC11 with IC50 of 191 nM, 27 nM and 5.4 nM, respectively. ^[1] In addition, CUDC-907 suppresses other types of HDAC enzymatic activity with lower potency. CUDC-907 inhibits the growth of a series of B cell lymphoma such as Granta 519, DOHH2, RL, Pfeiffer, SuDHL4, Daudi and Raji with IC50 of 7 nM, 1 nM, 2 nM, 4 nM, 3 nM, 15 nM and 9 nM, respectively. CUDC-907 also blocks the proliferation of Myeloma including RPMI8226, OPM-2 and ARH77 with IC50 of 2 nM, 1 nM and 5 nM, respectively. CUDC-907 displays greater anti-tumor activity in multiple myeloma and B cell lymphoma. ^[1]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
human Glioma cells (HF2885)	MVTDfZRwfG:6aXPpeJkh[XO\|YYm=		Mnf0O\|IhcA>?	NGXyOVFEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBIdGmxbXGgZ4VtdHNiKFjGNlg5PSliYX\0[ZIhPzJiaILzJIJ6KEOnbHz0bZRmekeubzDhd5NigSxiRVO1NF0xNjdibl2=	Ml[0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{OEi2PVkoRjJ4Mki4Olk6RC:jPh?=
human Glioma cells (HF3013)	NWTGRlJrS3m2b4TvfIlkcXS7IHHzd4F6		NGXUT5g4OiCq	MYTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDHcIlwdWFiY3XscJMhMEiIM{CxN{kh[W[2ZYKgO\|IhcHK\|IHL5JGNmdGy2aYTldmdtdyCjc4PhfUwhTUN3ME2wMlchdk1?	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJ6OE[5PUc,OjZ{OEi2PVk9N2F-
human Glioma cells (HF2876)	NWrDU2xvS3m2b4TvfIlkcXS7IHHzd4F6		NHTGSpg4OiCq	M4HvNmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGdtcW:vYTDj[YxteyBqSF[yPFc3MSCjZoTldkA4OiCqcoOgZpkhS2WubITpeIVzT2yxIHHzd4F6NCCHQ{WwQVAvPyCwTR?=	NFrXblE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkK4PFY6QSd-Mk[yPFg3QTl:L3G+
human Glioma cells (HF2790)	NIfh[JBEgXSxdH;4bYNqfHliYYPzZZk>		NFf5TZg4OiCq	NELKT5pEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBIdGmxbXGgZ4VtdHNiKFjGNlc6OCliYX\0[ZIhPzJiaILzJIJ6KEOnbHz0bZRmekeubzDhd5NigSxiRVO1NF0xNjdibl2=	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJ6OE[5PUc,OjZ{OEi2PVk9N2F-
human Glioma cells (HF2476)	M4[0OGN6fG:2b4jpZ4l1gSCjc4PhfS=>		M3fzZVczKGh?	M3y5[mN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGdtcW:vYTDj[YxteyBqSF[yOFc3MSCjZoTldkA4OiCqcoOgZpkhS2WubITpeIVzT2yxIHHzd4F6NCCHQ{WwQVAvPyCwTR?=	MnS3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{OEi2PVkoRjJ4Mki4Olk6RC:jPh?=
human Glioma cells (HF2381)	NF;zWVREgXSxdH;4bYNqfHliYYPzZZk>		M{H3UlczKGh?	M4nwemN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGdtcW:vYTDj[YxteyBqSF[yN\|gyMSCjZoTldkA4OiCqcoOgZpkhS2WubITpeIVzT2yxIHHzd4F6NCCHQ{WwQVAvPyCwTR?=	M1PHXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4Mki4Olk6Lz5{NkK4PFY6QTxxYU6=
human Glioma cells (HF2303)	M{PrN2N6fG:2b4jpZ4l1gSCjc4PhfS=>		M2n3O\|czKGh?	M3jFeGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGdtcW:vYTDj[YxteyBqSF[yN\|A{MSCjZoTldkA4OiCqcoOgZpkhS2WubITpeIVzT2yxIHHzd4F6NCCHQ{WwQVAvPyCwTR?=	M{PqTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4Mki4Olk6Lz5{NkK4PFY6QTxxYU6=
MV4-11	Mm\5R5l1d3SxeHnjbZR6KGG\|c3H5		MWKyOEBpenN?	MkTtR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUXY1NTFzIHPlcIx{KGG\|c3Xzd4VlKGG\|IHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDJ2IHjyd{BjgSCPVGSgZZN{[XluIE2wMlAxODR\|zszNMi=>	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzF6Nk[3Okc,OjdzOE[2O\|Y9N2F-
Sf9	MWLGeY5kfGmxbjDhd5NigQ>?		MXKxOUBucW6\|	NUXnS5VJUW6qaXLpeIlwdiCxZjDmeYxtKGynbnf0bEBENXSncn3pcoFtKEircz30ZYdo\WRiaIXtZY4hemWlb33ibY5idnRiSFTBR\|MwVkORUkKgLFM6PSC2bzC0PFkhemW\|aXT1[ZMqKGW6cILld5Nm\CCrbjDiZYN2dG:4aYL1d{Bqdm[nY4Tl[EBqdnOnY4SgV4Y6KGOnbHzzJJV{cW6pIFHjMZBmeHSrZHWtRW1EKGG\|IIP1ZpN1emG2ZTDhd5Nme3OnZDDhd{Bz\WynYYPlJI9nKEGPQzDwdoVqdmO3YnH0[YQh\m:{IEG1JI1qdnNiZn;scI94\WRiYomgd5Vje3S{LDC9NE4xODF6zszNMi=>	NGnmVoc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{G4OlY4Pid-MkexPFY3PzZ:L3G+
Sf9	NFK1W4hHfW6ldHnvckBie3OjeR?=		MY[xOUBucW6\|	Mmm3TY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCCKRFHDNVAh\XiycnXzd4VlKGmwIHLhZ5Vtd3[rcoXzJIlv\mWldHXkJIlve2WldDDT[lkh[2WubIOgeZNqdmdiQXOtdIVxfGmmZT3BUWMh[XNic4Xid5Rz[XSnIHHzd4V{e2WmIHHzJJJmdGWjc3Wgc4YhSU2FIIDy[Ylv[3WkYYTl[EBnd3JiMUWgcYlveyCob3zsc5dm\CCkeTDzeYJ{fHKjdHWgZYRlcXSrb36gcYVie3W{ZXSgZYZ1\XJiMTDodkBjgSCobIXvdoV{[2WwY3WgZZN{[XluIE2wMlAxOjkQvF2u	M2LEXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUi2Olc3Lz5{N{G4OlY4PjxxYU6=
Sf9	NIP0VWlHfW6ldHnvckBie3OjeR?=		MUWxOUBucW6\|	NHzVbmFKdmirYnn0bY9vKG:oIH\1cIwhdGWwZ4ToJIh2dWGwIILlZ49u[mmwYX70JGhFSUN{IHX4dJJme3OnZDDpckBj[WO3bH;2bZJ2eyCrbn\lZ5Rm\CCrboPlZ5QhW2Z7IHPlcIx{KHW\|aX7nJGFkNXCncITp[IUuSU2FIHHzJJN2[nO2cnH0[UBie3Onc4Pl[EBieyC{ZXzlZZNmKG:oIFHNR{BxemWrbnP1ZoF1\WRiZn;yJFE2KG2rboOg[o9tdG:5ZXSgZpkhe3Wkc4TyZZRmKGGmZHn0bY9vKG2nYYP1doVlKGGodHXyJFEhcHJiYomg[ox2d3Knc3PlcoNmKGFuIE2wMlAxPc7:TT6=	NE\CUZU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{G4OlY4Pid-MkexPFY3PzZ:L3G+
Sf9	MWPGeY5kfGmxbjDhd5NigQ>?		MV:xOUBucW6\|	M2S4W2lvcGmkaYTpc44hd2ZiZoXscEBt\W6pdHigbJVu[W5icnXjc41jcW6jboSgTGRCSzFzIHX4dJJme3OnZDDpckBj[WO3bH;2bZJ2eyCrbn\lZ5Rm\CCrboPlZ5QhW2Z7IHPlcIx{KHW\|aX7nJGFkNXCncITp[IUuSU2FIHHzJJN2[nO2cnH0[UBie3Onc4Pl[EBieyC{ZXzlZZNmKG:oIFHNR{BxemWrbnP1ZoF1\WRiZn;yJFE2KG2rboOg[o9tdG:5ZXSgZpkhe3Wkc4TyZZRmKGGmZHn0bY9vKG2nYYP1doVlKGGodHXyJFEhcHJiYomg[ox2d3Knc3PlcoNmKCxiPUCuNFA2PM7:TT6=	Mk\rQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzOE[2O\|YoRjJ5MUi2Olc3RC:jPh?=
A2780S	MXfDfZRwfG:6aXPpeJkh[XO\|YYm=		NEHJdXczPCCqcoO=	NG\zZpdEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCOjd6MGOgZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiMkSgbJJ{KGK7IF3UWEBie3OjeTygQVAvODB4MUZOwG0v	NVTvSpVMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkexPFY3PzZpPkK3NVg3Pjd4PD;hQi=>
HCT116	MnvmR5l1d3SxeHnjbZR6KGG\|c3H5		NGX1W2IzPCCqcoO=	M3jNN2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhEXDFzNjDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB{NDDodpMh[nliTWTUJIF{e2G7LDC9NE4xODd\|NN88UU4>	NGjISmc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{G4OlY4Pid-MkexPFY3PzZ:L3G+
Sf9	M3qwN2Z2dmO2aX;uJIF{e2G7		NYLxWWVnPjBibXnudy=>	MYPJcohq[mm2aX;uJI9nKG[3bHygcIVv\3SqIILlZ49u[mmwYX70JIh2dWGwIF6teIVzdWmwYXygS3NVNXSjZ3fl[EBxOTFyIHHsdIhiN3WwdHHn[4VlKHB6NTDhcJBp[SCneIDy[ZN{\WRiaX6gZoFkfWyxdnnyeZMhcW6oZXP0[YQhcW6\|ZXP0JHNnQSClZXzsd{B2e2mwZzDQTVo{WFNiYYOgd5Vje3S{YYTlJIlv[3WkYYTl[EBnd3JiNkCgcYlveyCkeTDBSHAuT2yxIHz1cYlv\XOlZX7j[UBie3OjeTygQVAvODF7zszNMi=>	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzF6Nk[3Okc,OjdzOE[2O\|Y9N2F-
Sf9	Mn3mSpVv[3Srb36gZZN{[Xl?		MmezNVUhdWmwcx?=	MYXJcohq[mm2aX;uJI9nKG[3bHygcIVv\3SqIHj1cYFvKHKnY3;tZolv[W62IFjERWM3KGW6cILld5Nm\CCrbjDiZYN2dG:4aYL1d{Bqdm[nY4Tl[EBqdnOnY4SgV4Y6KGOnbHzzJJV{cW6pIFHjMZBmeHSrZHWtRW1EKGG\|IIP1ZpN1emG2ZTDhd5Nme3OnZDDhd{Bz\WynYYPlJI9nKEGPQzDwdoVqdmO3YnH0[YQh\m:{IEG1JI1qdnNiZn;scI94\WRiYomgd5Vje3S{YYTlJIFl\Gm2aX;uJI1m[XO3cnXkJIFnfGW{IEGgbJIh[nliZnz1c5Jme2OnbnPlJIEtKD1yLkCyO:69VS5?	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzF6Nk[3Okc,OjdzOE[2O\|Y9N2F-
Sf9	NG\3W3ZHfW6ldHnvckBie3OjeR?=		NYPtfYZYOiCqcoO=	MVXJcohq[mm2aX;uJI9nKE5vdHXycYlv[WxiSHnzOk11[WepZXSgdoVkd22kaX7hcpQh\nWubD3s[Y5ofGhiaIXtZY4heDFzMHTlcJRiN3WwdHHn[4VlKHKnY3;tZolv[W62IH\1cIwhdGWwZ4ToJIh2dWGwIIC4OYFteGijIHX4dJJme3OnZDDpckBj[WO3bH;2bZJ2eyCrbn\lZ5Rm\CCrboPlZ5QhW2Z7IHPlcIx{KGmwY4XiZZRm\CCob4KgNkBpenNiYomgb4lv[XOnLXfsc{Bie3OjeTygQVAvODN7zszNMi=>	NWjidFB[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkexPFY3PzZpPkK3NVg3Pjd4PD;hQi=>
Sf9	MkXWSpVv[3Srb36gZZN{[Xl?		NVjrS4V4OSCqch?=	NXzFb4dwUW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBpfW2jbjDwNVEx[mW2YTDlfJBz\XO\|ZXSgbY4h[mGldXzveolzfXNiaX7m[YN1\WRiaX7z[YN1KFOoOTDj[YxteyCrbnP1ZoF1\WRiZn;yJFEhcHJiYomgRWRRNWeub4LlZYdmdiCjc4PhfUwhRTBwMEW0{txONg>?	NXPPNZZkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkexPFY3PzZpPkK3NVg3Pjd4PD;hQi=>
A2780S	NYW0enF5TnWwY4Tpc44h[XO\|YYm=		MnHmOkBpenN?	M4LzRmlvcGmkaYTpc44hd2ZiSFTBR\|EwOi9\|IHnuJIh2dWGwIFGyO\|gxWyClZXzsd{Bie3Onc4Pl[EBieyCqaYP0c45mKEh\|IHHj[ZR6dGG2aX;uJIlv[3WkYYTl[EBnd3JiNjDodpMh[nliY4n0c4Jtd3RiYYPzZZktKD1yLkGyOlI2\|ryPLh?=	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzF6Nk[3Okc,OjdzOE[2O\|Y9N2F-
Sf9	NVv5Rm9HTnWwY4Tpc44h[XO\|YYm=		MYGxOUBucW6\|	M3fZOGlvcGmkaYTpc44hd2ZiZoXscEBt\W6pdHigR{11\XKvaX7hcEBJcXNvdHHn[4VlKGi3bXHuJJJm[2:vYnnuZY51KEiGQVO4JIV5eHKnc4Pl[EBqdiCkYXP1cI93cXK3czDpcoZm[3SnZDDpcpNm[3RiU3[5JINmdGy\|IIXzbY5oKEGlLYDldJRq\GVvQV3DJIF{KHO3YoP0doF1\SCjc4Pld5Nm\CCjczDy[Yxm[XOnIH;mJGFOSyCycnXpcoN2[mG2ZXSg[o9zKDF3IH3pcpMh\m:ubH;3[YQh[nlic4Xid5Rz[XSnIHHk[Il1cW:wIH3lZZN2emWmIHHmeIVzKCxiPUCuNVky\|ryPLh?=	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzF6Nk[3Okc,OjdzOE[2O\|Y9N2F-
A2780S	M3fncGZ2dmO2aX;uJIF{e2G7		M{jIbFYhcHK\|	NGL5Uo9KdmirYnn0bY9vKG:oIFjERWM3KGmwIHj1cYFvKEF{N{iwV{Bk\WyuczDhd5Nme3OnZDDhd{B1fWK3bHnuJIFk\XS7bHH0bY9vKGmwY4XiZZRm\CCob4KgOkBpenNiYomgZ5l1d2Kub4SgZZN{[XluIE2wMlIzOTd3zszNMi=>	NFTNSVg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{G4OlY4Pid-MkexPFY3PzZ:L3G+
Sf9	NEexSFJHfW6ldHnvckBie3OjeR?=		NXnZO5d{OTVibXnudy=>	M3jibWlvcGmkaYTpc44hd2ZiTj30[ZJucW6jbDDHV3QwSy22ZYLtbY5idCCKaYOteIFo\2WmIHj1cYFvKHKnY3;tZolv[W62IFjERWM1KCh4MkegeI8hOTB6NDDy[ZNq\HWnczmg[ZhxemW\|c3XkJIlvKGKjY4Xsc5ZqenW\|IHnu[oVkfGWmIHnud4VkfCCVZkmgZ4VtdHNidYPpcochSWNvcHXweIll\S2DTVOgZZMhe3Wkc4TyZZRmKGG\|c3Xzd4VlKGG\|IILlcIVie2Vib3[gRW1EKHC{ZXnuZ5Vj[XSnZDDmc5IhOTVibXnud{Bnd2yub4fl[EBjgSC\|dXLzeJJifCxiPUCuOFA6\|ryPLh?=	NXfnV2VpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkexPFY3PzZpPkK3NVg3Pjd4PD;hQi=>
Sf9	MYDGeY5kfGmxbjDhd5NigQ>?		MmjzNVUhdWmwcx?=	MXfJcohq[mm2aX;uJI9nKE5vdHXycYlv[WxiR2PUMZRi\2enZDDoeY1idiC{ZXPvcYJqdmGwdDDISGFEPyBqNUG4JJRwKGWwZDDy[ZNq\HWnczmg[ZhxemW\|c3XkJIlvKGKjY4Xsc5ZqenW\|IHnu[oVkfGWmIHnud4VkfCCVZkmgZ4VtdHNidYPpcochSWNvcHXweIll\S2DTVOgZZMhe3Wkc4TyZZRmKGG\|c3Xzd4VlKGG\|IILlcIVie2Vib3[gRW1EKHC{ZXnuZ5Vj[XSnZDDmc5IhOTVibXnud{Bnd2yub4fl[EBjgSC\|dXLzeJJifGViYXTkbZRqd25ibXXhd5UtKD1yLkSyOu69VS5?	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzF6Nk[3Okc,OjdzOE[2O\|Y9N2F-
Sf9	NXXP[Hp{TnWwY4Tpc44h[XO\|YYm=		Mor2NVUhdWmwcx?=	NUjN[lN{UW6qaXLpeIlwdiCxZjDDMZRmem2rbnHsJGhqey22YXfn[YQhcHWvYX6gdoVkd22kaX7hcpQhUESDQ{mgLFYxPCC2bzCxNFY3KHKnc3nkeYV{MSCneIDy[ZN{\WRiaX6gZoFkfWyxdnnyeZMhcW6oZXP0[YQhcW6\|ZXP0JHNnQSClZXzsd{B2e2mwZzDBZ{1x\XC2aXTlMWFOSyCjczDzeYJ{fHKjdHWgZZN{\XO\|ZXSgZZMhemWuZXHz[UBw\iCDTVOgdJJmcW6ldXLheIVlKG[xcjCxOUBucW6\|IH\vcIxwf2WmIHL5JJN2[nO2cnH0[UBi\GSrdHnvckBu\WG\|LDC9NE42PTUQvF2u	M37oeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUi2Olc3Lz5{N{G4OlY4PjxxYU6=
Sf9	NIm1V3lHfW6ldHnvckBie3OjeR?=		NG\KUmkyPSCvaX7z	MXLJcohq[mm2aX;uJI9nKGi3bXHuJJJm[2:vYnnuZY51KEiGQVO1JIV5eHKnc4Pl[EBqdiCkYXP1cI93cXK3czDpcoZm[3SnZDDpcpNm[3RiU3[5JINmdGy\|IIXzbY5oKEGlLYDldJRq\GVvQV3DJIF{KHO3YoP0doF1\SCjc4Pld5Nm\CCjczDy[Yxm[XOnIH;mJGFOSyCycnXpcoN2[mG2ZXSg[o9zKDF3IH3pcpMh\m:ubH;3[YQh[nlic4Xid5Rz[XSnIHHk[Il1cW:wIH3lZZN2emWmIHHmeIVzKDFiaIKgZpkh\my3b4Lld4NmdmOnIHHzd4F6NCB;MD62O\|TPxE1w	MmPzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzOE[2O\|YoRjJ5MUi2Olc3RC:jPh?=
Sf9	NGe5O4pHfW6ldHnvckBie3OjeR?=			Mn\TTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDmeYxtKGynbnf0bEBpfW2jbjDOMZRmem2rbnHsJGdUXC22YXfn[YQhWEl\|SzDwNVEx[WyyaHGveY51[WepZXSgdFg2[WyyaHGg[ZhxemW\|c3XkJIlvKGKjY4Xsc5ZqenW\|IHnu[oVkfGWmIHnud4VkfCCVZkmgZ4VtdHNiYomgRWRRNUeubzDseY1qdmW\|Y3XueEBie3OjeTygQVAvODF7zszNMi=>	M{PiVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEm0NlU3Lz5{OES5OFI2PjxxYU6=
Sf9	MmXqSpVv[3Srb36gZZN{[Xl?			Ml\GTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDmeYxtKGynbnf0bEBpfW2jbjDOMZRmem2rbnHsJGdUXC22YXfn[YQhWEl\|SzDwNVEx\GWudHGveY51[WepZXSgdFg2[WyyaHGg[ZhxemW\|c3XkJIlvKGKjY4Xsc5ZqenW\|IHnu[oVkfGWmIHnud4VkfCCVZkmgZ4VtdHNiYomgRWRRNUeubzDseY1qdmW\|Y3XueEBie3OjeTygQVAvODN7zszNMi=>	NXPaNpltRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0PVQzPTZpPkK4OFk1OjV4PD;hQi=>
Sf9	MXnGeY5kfGmxbjDhd5NigQ>?			NUDyWJV4UW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBnfWyuIHzlcod1cCCqdX3hckBPNXSncn3pcoFtKEeVVD30ZYdo\WRiUFmzT{BxOTFyYnX0ZU92dnSjZ3fl[EBxQDWjbIDoZUBmgHC{ZYPz[YQhcW5iYnHjeYxwfmm{dYOgbY5n\WO2ZXSgbY5{\WO2IGPmPUBk\WyuczDifUBCTFBvR3zvJIx2dWmwZYPj[Y51KGG\|c3H5MEA:OC5yNUVOwG0v	M3vZVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEm0NlU3Lz5{OES5OFI2PjxxYU6=
TC32	NYrHbWFOeUiWUzDhd5NigQ>?			MVPxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhXEN\|MjDj[Yxtew>?	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
DAOY	NGj2[\|dyUFSVIHHzd4F6			NWS0UIVMeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFTBU3kh[2WubIO=	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SJ-GBM2	NY\WfVJQeUiWUzDhd5NigQ>?			MXjxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0pvR1LNNkBk\Wyucx?=	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
A673	M{PGRpFJXFNiYYPzZZk>			NXW0Um9peUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFG2O\|Mh[2WubIO=	NEnQbY09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SK-N-MC	M1:xfZFJXFNiYYPzZZk>			MVzxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0tvTj3NR{Bk\Wyucx?=	M12xbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-37	NWjYXnZDeUiWUzDhd5NigQ>?			MlrYdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKEKWLUO3JINmdGy\|	NVL2WIlVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB-EBc1	MnvtdWhVWyCjc4PhfS=>			NWS1VZNLeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF7CMWVD[zFiY3XscJM>	NEHzO4o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
U-2 OS	MoTFdWhVWyCjc4PhfS=>			MWPxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhXS1{IF;TJINmdGy\|	MnvSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Saos-2	NH:3cXFyUFSVIHHzd4F6			NXf3PWx{eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPhc5MuOiClZXzsdy=>	NHjDSIk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SK-N-SH	NEfQW2RyUFSVIHHzd4F6			NFz0Z\|NyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1UUCClZXzsdy=>	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
NB1643	M{fJeZFJXFNiYYPzZZk>			MW\xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVkJzNkSzJINmdGy\|	NXnJW4R5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
LAN-5	MVzxTHRUKGG\|c3H5			NGDhSWdyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTFHOMVUh[2WubIO=	MmSyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
BT-12	NWfycow6eUiWUzDhd5NigQ>?			NUewRXdxeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFLUMVEzKGOnbHzz	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Rh18	MXfxTHRUKGG\|c3H5			Mof3dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKqMUigZ4VtdHN?	Mn\SQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
OHS-50	MlPZdWhVWyCjc4PhfS=>			M2K3RpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCRSGOtOVAh[2WubIO=	M{jwfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
RD	NW\3T\|VseUiWUzDhd5NigQ>?			M1j1fZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCURDDj[Yxtew>?	MkDLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
MG 63 (6-TG R)	M2fDNpFJXFNiYYPzZZk>			MVrxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVUdiNkOgLFYuXEdiUjmgZ4VtdHN?	M1nqXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh30	NWrvb2xseUiWUzDhd5NigQ>?			MlPDdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKqM{CgZ4VtdHN?	NF3UbY09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
Rh41	NUC2NZFQeUiWUzDhd5NigQ>?			NGj2eGFyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUni0NUBk\Wyucx?=	Mn;EQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
NB1643	NVS3fHVVeUiWUzDhd5NigQ>?			M{LIcZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJG5DOTZ2MzDj[Yxtew>?	M{CzT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
A673	NWToOY9leUiWUzDhd5NigQ>?			NFva[IVyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBCPjd\|IHPlcIx{MQ>?	NXLVUXJkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-12	M{TCRpFJXFNiYYPzZZk>			MmG5dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgRnQuOTJiY3XscJM>	M1HDR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
LAN-5	NHqxOlNyUFSVIHHzd4F6			MYnxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDMRW4uPSClZXzsdy=>	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
DAOY	NVqydZZXeUiWUzDhd5NigQ>?			NWn3b5J4eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhTEGRWTDj[Yxtew>?	MmTnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
MG 63 (6-TG R)	M2i2U5FJXFNiYYPzZZk>			M4jQV5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJG1IKDZ\|IDi2MXRIKFJrIHPlcIx{	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
U-2 OS	NXfwfXdoeUiWUzDhd5NigQ>?			M134PJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHUuOiCRUzDj[Yxtew>?	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Rh41	M3X0OpFJXFNiYYPzZZk>			M2DnRZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHJpPDFiY3XscJM>	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
RD	MYTxTHRUKGG\|c3H5			NXfPR5pGeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhWkRiY3XscJM>	NXHaZZRCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh18	NUnVdVhYeUiWUzDhd5NigQ>?			M1\E[pFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHJpOThiY3XscJM>	NF\XW3M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
Rh30	MX;xTHRUKGG\|c3H5			M2\DcJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHJpOzBiY3XscJM>	NV2zWIpWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-SH	MorCdWhVWyCjc4PhfS=>			NFLhTppyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBUUy2QLWPIJINmdGy\|	NFzSfXU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SK-N-SH	NH\OO4ZyUFSVIHHzd4F6			NIj2dFVyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCRcoToc4dwdmGuIEPEJJZq[WKrbHn0fUB{[3KnZX6g[o9zKFONLV6tV2gh[2WubIO=	M1PrUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SJ-GBM2	M1PQNpFJXFNiYYPzZZk>			Ml:4dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohV3K2aH;nc45idCB\|RDD2bYFjcWyrdImgd4Nz\WWwIH\vdkBUUi2JQl2yJINmdGy\|	NV3sUXpKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Daoy	MXjxTHRUKGG\|c3H5			NHqxeHdyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCRcoToc4dwdmGuIEPEJJZq[WKrbHn0fUB{[3KnZX6g[o9zKESjb4mgZ4VtdHN?	Mnj2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Sf9	MnPwSpVv[3Srb36gZZN{[Xl?			Mk\ZTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDoeY1idiCodXzsMYxmdme2aDDOMZRmem2rbnHsJGdUXC22YXfn[YQheDFzMHHsdIhiN3WwdHHn[4VlKG[3bHytcIVv\3SqIIC4OYFteGijIHX4dJJme3OnZDDpckBj[WO3bH;2bZJ2eyCrbn\lZ5Rm\CCVZkmgZ4VtdHNidYPpcochWEmSMjDhd{B{fWK\|dILheIUh[nliQVTQMYdtdyCudX3pcoV{[2WwY3WgZZN{[XluIE2wMlAyQc7:TT6=	NHL5TWY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MESxPFc3Pid-M{C0NVg4PjZ:L3G+
Sf9	NFK2OmJHfW6ldHnvckBie3OjeR?=			NH:0[G5KdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JIh2dWGwIH\1cIwudGWwZ4ToJG4ufGW{bXnuZYwhT1OWLYTh[4dm\CCyMUGw[IVtfGFxdX70ZYdo\WRiZoXscE1t\W6pdHigdFg2[WyyaHGg[ZhxemW\|c3XkJIlvKGKjY4Xsc5ZqenW\|IHnu[oVkfGWmIGPmPUBk\WyuczD1d4lv\yCSSWCyJIF{KHO3YoP0doF1\SCkeTDBSHAu\2yxIHz1cYlv\XOlZX7j[UBie3OjeTygQVAvODN7zszNMi=>	NEO4OXE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MESxPFc3Pid-M{C0NVg4PjZ:L3G+
Sf9	M3vVWWZ2dmO2aX;uJIF{e2G7			NEXaTYZKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JIh2dWGwIH\1cIwudGWwZ4ToJG4ufGW{bXnuZYwhT1OWLYTh[4dm\CCyMUGwZoV1[S:3boTh[4dm\CCodXzsMYxmdme2aDDwPFVidHCqYTDlfJBz\XO\|ZXSgbY4h[mGldXzveolzfXNiaX7m[YN1\WRiU3[5JINmdGy\|IIXzbY5oKFCLUEKgZZMhe3Wkc4TyZZRmKGK7IFHEVE1odG9ibIXtbY5me2OnbnPlJIF{e2G7LDC9NE4xPTUQvF2u	NYDGe3BnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{C0NVg4PjZpPkOwOFE5PzZ4PD;hQi=>
Sf9	NIjORplHfW6ldHnvckBie3OjeR?=		MkO4NVUhdWmwcx?=	MkjTTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDDMZRmem2rbnHsJGhqey:ITFHHMZRi\2enZDDISGFEOSBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDiZYN2dG:4aYL1d{Bqdm[nY4Tl[EBU\jliaX7z[YN1KGOnbHzzJJV{cW6pIFHjMZBmeHSrZHWgZZMhe3Wkc4TyZZRmKHC{ZXnuZ5Vj[XSnZDDmc5IhOTVibXnud{Bnd2yub4fl[EBjgSC\|dXLzeJJifGViYXTkbZRqd25iYX7kJI1m[XO3cnXkJIFnfGW{IEGgbJItKD1yLkCwNFM3\|ryPLh?=	Mom4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzFzMUe1NVcoRjNzMUG3OVE4RC:jPh?=
Sf9	Mo\DSpVv[3Srb36gZZN{[Xl?		NXr1TYd[OTVibXnudy=>	M3;sXWlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgbJVu[W5iZoXscEBt\W6pdHigR{11\XKvaX7hcEBJcXNvdHHn[4VlKEiGQVO4JIV5eHKnc4Pl[EBqdiCkYXP1cI93cXK3czDpcoZm[3SnZDDT[lkhcW6\|ZXP0JINmdGy\|IIXzbY5oKEGlLYDldJRq\GViYYOgd5Vje3S{YYTlJJBz\WmwY4XiZZRm\CCob4KgNVUhdWmwczDmc4xtd3enZDDifUB{fWK\|dILheIUh[WSmaYTpc44h[W6mIH3lZZN2emWmIHHmeIVzKDFiaIKsJF0xNjByMUVOwG0v	M4[1dVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNzMUG3OVE4Lz5\|MUGxO\|UyPzxxYU6=
Sf9	Mk\HSpVv[3Srb36gZZN{[Xl?		M2TJcFE2KG2rboO=	NHS5RYtKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JIh2dWGwIH\1cIwhdGWwZ4ToJGhFSUN{IHX4dJJme3OnZDDpckBj[WO3bH;2bZJ2eyCrbn\lZ5Rm\CCVZkmgbY5{\WO2IHPlcIx{KHW\|aX7nJGFkNXCncITp[IUh[XNic4Xid5Rz[XSnIIDy[Ylv[3WkYYTl[EBnd3JiMUWgcYlveyCob3zsc5dm\CCkeTDzeYJ{fHKjdHWgZYRlcXSrb36gZY5lKG2nYYP1doVlKGGodHXyJFEhcHJuIE2wMlAxOTcQvF2u	NHjxTG49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MUGxO\|UyPyd-M{GxNVc2OTd:L3G+
HCT116	NH;wWVNCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NVvTRWliQTZiaILz	NGP5XpRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjDWFEyPiClZXzsd{Bi\nSncjC5OkBpenNiYomgUXRVKGG\|c3H5MEA:OC5yMEZOwG0v	NFjBTJI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MUGxO\|UyPyd-M{GxNVc2OTd:L3G+
HCT8	M4DlWGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MWO5OkBpenN?	NV7yNppsSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIR3Q5KGOnbHzzJIFnfGW{IEm2JIhzeyCkeTDNWHQh[XO\|YYmsJF0xNjByNd88UU4>	NXjyO5hHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{GxNVc2OTdpPkOxNVE4PTF5PD;hQi=>
U87	MlXmRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NU\hSIVvQTZiaILz	NUni[XZ1SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDVPFch[2WubIOgZYZ1\XJiOU[gbJJ{KGK7IF3UWEBie3OjeTygQVAvODB5zszNMi=>	NFixTpQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MUGxO\|UyPyd-M{GxNVc2OTd:L3G+
Capan2	NXLoS4FQSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MoDDPVYhcHK\|	M4PvSWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQ3HwZY4zKGOnbHzzJIFnfGW{IEm2JIhzeyCkeTDNWHQh[XO\|YYmsJF0xNjByN988UU4>	M1vZVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNzMUG3OVE4Lz5\|MUGxO\|UyPzxxYU6=
MDA-MB-453	NVXJTmt1SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MnjiPVYhcHK\|	NYDH[pczSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvNEWzJINmdGy\|IHHmeIVzKDl4IHjyd{BjgSCPVGSgZZN{[XluIE2wMlAxQc7:TT6=	NX3Qc2NbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{GxNVc2OTdpPkOxNVE4PTF5PD;hQi=>
Bel7402	MkDvRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		Ml;0PVYhcHK\|	NYf5ZoNOSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDC[Yw4PDB{IHPlcIx{KGGodHXyJFk3KGi{czDifUBOXFRiYYPzZZktKD1yLkCxN:69VS5?	MoP0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzFzMUe1NVcoRjNzMUG3OVE4RC:jPh?=
HepG2	NHe0bmxCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NHHscoE6PiCqcoO=	MoPCRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKZYDHNkBk\WyuczDh[pRmeiB7NjDodpMh[nliTWTUJIF{e2G7LDC9NE4xOTYQvF2u	MnPLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzFzMUe1NVcoRjNzMUG3OVE4RC:jPh?=
NCI-H1299	MWDBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MVK5OkBpenN?	NFG4emVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF7DTU1JOTJ7OTDj[YxteyCjZoTldkA6PiCqcoOgZpkhVVSWIHHzd4F6NCB;MD6wNlXPxE1w	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{OTFzN{WxO{c,OzFzMUe1NVc9N2F-
MCF7	NV73[XVDSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MUS5OkBpenN?	NXHs[ZZPSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IEm2JIhzeyCkeTDNWHQh[XO\|YYmsJF0xNjB2Md88UU4>	M37ENlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNzMUG3OVE4Lz5\|MUGxO\|UyPzxxYU6=
HGC27	NX;ZWldJSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NFLYPJY6PiCqcoO=	MnrRRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKR1OyO{Bk\WyuczDh[pRmeiB7NjDodpMh[nliTWTUJIF{e2G7LDC9NE4xPDIQvF2u	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{OTFzN{WxO{c,OzFzMUe1NVc9N2F-
Sf9	MUPGeY5kfGmxbjDhd5NigQ>?		MXexOUBucW6\|	M2TqZWlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgbJVu[W5iZoXscEBt\W6pdHigTGRCSzFzIHX4dJJme3OnZDDpckBj[WO3bH;2bZJ2eyCrbn\lZ5Rm\CCVZkmgbY5{\WO2IHPlcIx{KHW\|aX7nJGFkNXCncITp[IUh[XNic4Xid5Rz[XSnIIDy[Ylv[3WkYYTl[EBnd3JiMUWgcYlveyCob3zsc5dm\CCkeTDzeYJ{fHKjdHWgZYRlcXSrb36gZY5lKG2nYYP1doVlKGGodHXyJFEhcHJuIE2wMlE{Os7:TT6=	NGq2bnA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MUGxO\|UyPyd-M{GxNVc2OTd:L3G+
NCI-H460	NYTjSGRkSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NGLRZ\|Y6PiCqcoO=	Mor1RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCQQ1mtTFQ3OCClZXzsd{Bi\nSncjC5OkBpenNiYomgUXRVKGG\|c3H5MEA:OC5zNd88UU4>	M3rJOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNzMUG3OVE4Lz5\|MUGxO\|UyPzxxYU6=
SW1990	NX;6WVM5SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MlP6PVYhcHK\|	NWPBbm9oSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDTW\|E6QTBiY3XscJMh[W[2ZYKgPVYhcHK\|IHL5JG1VXCCjc4PhfUwhRTBwMUlOwG0v	MkO0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzFzMUe1NVcoRjNzMUG3OVE4RC:jPh?=
K562	M33i[GFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NGSwXGQ6PiCqcoO=	NX;rNmVESW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDLOVYzKGOnbHzzJIFnfGW{IEm2JIhzeyCkeTDNWHQh[XO\|YYmsJF0xNjJ6zszNMi=>	NWTxS49ORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{GxNVc2OTdpPkOxNVE4PTF5PD;hQi=>
Sf9	M1jBfGZ2dmO2aX;uJIF{e2G7		MYCxOUBucW6\|	MmX6TY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDoeY1idiCodXzsJIxmdme2aDDISGFEPCCneIDy[ZN{\WRiaX6gZoFkfWyxdnnyeZMhcW6oZXP0[YQhW2Z7IHnud4VkfCClZXzsd{B2e2mwZzDBZ{1x\XC2aXTlJIF{KHO3YoP0doF1\SCycnXpcoN2[mG2ZXSg[o9zKDF3IH3pcpMh\m:ubH;3[YQh[nlic4Xid5Rz[XSnIHHk[Il1cW:wIHHu[EBu\WG\|dYLl[EBi\nSncjCxJIhzNCB;MD60OFXPxE1w	NUjQcGU4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{GxNVc2OTdpPkOxNVE4PTF5PD;hQi=>
DU145	M1[2[WFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NV:0O2t{QTZiaILz	MXvBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKESXMUS1JINmdGy\|IHHmeIVzKDl4IHjyd{BjgSCPVGSgZZN{[XluIE2wMlU3\|ryPLh?=	MlOxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzFzMUe1NVcoRjNzMUG3OVE4RC:jPh?=
HuH7	Mmf3RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NHyxZlY6PiCqcoO=	MkHpRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKdVi3JINmdGy\|IHHmeIVzKDl4IHjyd{BjgSCPVGSgZZN{[XluIE2wMlU3\|ryPLh?=	M{PHS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNzMUG3OVE4Lz5\|MUGxO\|UyPzxxYU6=
MV4-11	M1XKTWFvfGmycn;sbYZmemG2aY\lJIF{e2G7	NG\oNHkzPSC2bzC1NEBvVQ>?	MY[3NkBpenN?	NH72cZdCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3WOE0yOSClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gZ4VtdCC4aXHibYxqfHliYYSgNlUhfG9iNUCgcm0h[W[2ZYKgO\|IhcHK\|IHL5JJRzgXCqYX6gZox2\SCjc4PhfS=>	NEKxcYY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MkKxNlc{OCd-M{KyNVI4OzB:L3G+

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	AKT / p-AKT / P-p70S6K1 / Ac-H3K9 / p-MEK / p-ERK / p-STAT3 / MCL-1 / Bcl-2 / Bcl-xl / PARP; PubMed: 30353642 J Cell Mol Med Western blots showing protein expression in lysates of MEC-1 cells treated with CUDC-907 at various concentrations or DMSO as a control (0) for 12 h. AKT, p-AKT (Ser473), p-p70S6K (Thr389), Ac-H3K9, ERK, p-ERK (Thr202/Tyr204), p-MEK (Ser217/221), STAT3, p-STAT3 (Tyr705), MCL-1, BCL-2, BCL-xL, and PARP were detected with specific antibodies. β-actin was used as a loading control. p-PRAS40 / p-4EBP1 / p-S6 / c-Myc / Cleaved PARP / Caspase-3 / Celaved caspase-3 ; PubMed: 28147336 Oncotarget Western blot analysis demonstrating the effect of increasing concentration of CUDC-907 (from 0.01 to 1 μM) on PI3K downstream targets (p4EBP1, pPRAS40 and pS6) and histone H3 acetylation (Ac Histone H3). The actual inhibition of PI3K and HDAC resulted in a decrease in c-Myc protein levels. Activation of caspase 3 and PARP was present as well. SYK / BTK / Bcl-10 / MyD88 / IRAK4 ; PubMed: 28147336 Oncotarget Western blot confirming the effect of CUDC-907 (0.1 μM for 24 hours) on BCR and TLR signaling proteins in B-cell lymphoma cell lines (GCB n = 3 and ABC n = 3).	30353642 28147336
Immunofluorescence	γ-H2AX / 53BP1; PubMed: 29760046 Cancer Res Representative images and quantification of immunofluorescence staining for γH2AX and 53BP1 in SF188 cells treated with radiotherapy (4 Gy), CUDC-907 (100 nmol/L), or combination treatment in which radiotherapy was combined with KU70 siRNA, RAD51 siRNA (48 hours after siRNA transfection), or CUDC-907 (16 hours prior to 4 Gy). RAD51; PubMed: 29760046 Cancer Res Representative images and quantification of immunofluorescence staining for γH2AX and RAD51 in SF188 cells treated with radiotherapy (4 Gy), CUDC-907 (100 nmol/L), or combination treatment in which radiotherapy was combined with KU70 siRNA, RAD51 siRNA (48 hours after siRNA transfection), or CUDC-907 (16 hours prior to 4 Gy).	29760046
Growth inhibition assay	Cell viability; PubMed: 28147336 Oncotarget MTS assay of 8 representative DLBCL and 2 Hodgkin lymphoma cell lines treated with increasing dose of CUDC-907 from 0.01 to 10 μM for 24, 48, 72 hours. Error bars represent standard error of the mean (S.E.M) of triplicate experiments.	28147336

In vivo

CUDC-907 has a long half-life in murine tumors. CUDC-907 induces apoptosis and inhibits cancer cell proliferation in xenograft tumors. ^[1] In efficacy studies in NHL and MM models, CUDC-907 is more efficacious than either a single-agent PI3K or HDAC inhibitor reference compound or a combination of the two agents given at maximally tolerated doses (MTD). Furthermore, CUDC-907 is more efficacious than the PI3Kδ-selective inhibitor CAL-101 when dosed at MTD doses. ^[1]

Protocol

Animal Research: ^[1]	- Collapse Animal Models: NHL and MM models in mice Dosages: 100 mg/kg Administration: Administered via p.o. (Only for Reference)

References

[1] Qian C, et al. Clin Cancer Res. 2012, 18(15):4104-13.

Solubility (25°C)

In vitro	DMSO	102 mg/mL (200.57 mM)
	Water	Insoluble
	Ethanol	Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Fimepinostat (CUDC-907) SDF

Molecular Weight	508.55
Formula	C₂₃H₂₄N₈O₄S
CAS No.	1339928-25-4
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CN(CC1=CC2=C(S1)C(=NC(=N2)C3=CN=C(C=C3)OC)N4CCOCC4)C5=NC=C(C=N5)C(=O)NO

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-09-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02909777	Recruiting	Drug: CUDC-907	Lymphoma\|Neuroblastoma\|Brain Tumor\|Solid Tumor	Dana-Farber Cancer Institute\|Curis Inc.	October 2016	Phase 1
NCT02674750	Completed	Drug: CUDC-907	Relapsed and/or Refractory Diffuse Large B-cell Lymphoma Including With Myc Alterations	Curis Inc.	January 2016	Phase 2
NCT02307240	Completed	Drug: CUDC-907	Triple-Negative Breast Cancer\|High-grade Serous Ovarian Cancer\|Solid Tumors\|NUT Midline Carcinoma	Curis Inc.	November 2014	Phase 1
NCT01742988	Completed	Drug: fimepinostat\|Drug: Rituximab\|Drug: venetoclax	Lymphoma\|Relapsed Lymphoma\|Refractory Lymphoma\|Relapsed and/or Refractory Lymphoma\|Relapsed Ddiffuse Large B-Cell Lymphoma (DLBCL)\|Refractory Diffuse Large B-Cell Lymphoma (DLBCL)\|Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)\|Double-hit Lymphoma (DHL)\|Triple-hit Lymphoma (THL)\|Double-expressor Lymphoma (DEL)\|High-grade B-cell Lymphoma (HGBL)	Curis Inc.\|The Leukemia and Lymphoma Society	December 2012	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
How to solve CUDC-907 for in vivo studies (p.o.)?
Answer:
If you decided to take P.O. as your administration route, we suggest you to use 1% CMC-Na to dilute CUDC-907 as a suspension solution for gavage.
Question 2:
What is the half-life of CUDC-907 in vivo?
Answer:
GUDC-907 is said to have a long half-life in mouse tumor model: http://cancerres.aacrjournals.org/content/72/8_Supplement/3744.short, however, its not formally published and we have no detail of how long it is.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Selective HDAC Inhibitors

Rocilinostat (ACY-1215) : HDAC5-selective, IC50=5 nM.
Most Potent HDAC Inhibitor

Quisinostat (JNJ-26481585) : HDAC1, IC50=0.11 nM; HDAC2, IC50=0.33 nM.
FDA-approved HDAC Inhibitor

Vorinostat (SAHA, MK0683) : Approved by FDA against cutaneous T cell lymphoma.
Newest HDAC Inhibitor

RG2833 (RGFP109) ^New : Brain-penetrant HDAC inhibitor with IC50 of 60 nM and 50 nM for HDAC1 and HDAC3, respectively.

Related HDAC Products

CAY10603 ^New

CAY10603 (BML-281) is a potent and selective HDAC6 inhibitor with IC50 of 2 pM, >200-fold selectivity over other HDACs.
Domatinostat (4SC-202) ^New

Domatinostat (4SC-202) is a selective class I HDAC inhibitor with IC50 of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively. Also displays inhibitory activity against Lysine specific demethylase 1 (LSD1). Phase 1.
Panobinostat (LBH589)

Panobinostat (LBH589, NVP-LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Panobinostat (LBH589) induces autophagy and apoptosis. Panobinostat effectively disrupts HIV latency in vivo. Phase 3.
Vorinostat (SAHA)

Vorinostat (suberoylanilide hydroxamic acid, SAHA, MK0683, Zolinza) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay. Vorinostat abrogates productive HPV-18 DNA amplification.
Entinostat (MS-275)

Entinostat (MS-275, SNDX-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Entinostat induces autophagy and apoptosis. Phase 3.
Trichostatin A (TSA)

Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.
Romidepsin (FK228, Depsipeptide)

Romidepsin (FK228, Depsipeptide, FR 901228, NSC 630176) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively. Romidepsin (FK228/depsipeptide) controls growth and induces apoptosis in neuroblastoma tumor cells.

Features:More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.
Tubastatin A

Tubastatin A is a potent and selective HDAC6 inhibitor with IC50 of 15 nM in a cell-free assay. It is selective against all the other isozymes (1000-fold) except HDAC8 (57-fold). Tubastatin A promotes autophagy and increases apoptosis.
Mocetinostat (MGCD0103)

Mocetinostat (MGCD0103, MG0103) is a potent HDAC inhibitor with most potency for HDAC1 with IC50 of 0.15 μM in a cell-free assay, 2- to 10- fold selectivity against HDAC2, 3, and 11, and no activity to HDAC4, 5, 6, 7, and 8. Mocetinostat (MGCD0103) induces apoptosis and autophagy. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Fimepinostat (CUDC-907)